“Democratizing Infertility – A Severely Underserved Global Market” – INVO Bioscience (NASDAQ: INVO) CEO Interview 4-13-2021

Published Apr 13, 2021
Biotech & Healthcare
INVO Bioscience

By John F. Heerdink, Jr.

We were excited to host Tribe Public’s Webinar Presentation and Q&A Event which was held Wednesday, April 13 (8:30 am PT/ 11:30 am ET). Mr. Steve Shum, Chief Executive Officer in CEO of INVO Bioscience (NASDAQ: INVO) delivered a presentation titled “Democratizing Infertility – A Severely Underserved Global Market.” He was also available for a 5-10 minute Q&A session at the end of the presentation. INVO Bioscience (NASDAQ: INVO) is a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Their solution, the INVO® Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Their mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. Disclaimer: https://tribepublic.com/disclaimers.